JP2008536920A - 酸化還元反応によるタンパク質の結合特異性の改変方法 - Google Patents

酸化還元反応によるタンパク質の結合特異性の改変方法 Download PDF

Info

Publication number
JP2008536920A
JP2008536920A JP2008507693A JP2008507693A JP2008536920A JP 2008536920 A JP2008536920 A JP 2008536920A JP 2008507693 A JP2008507693 A JP 2008507693A JP 2008507693 A JP2008507693 A JP 2008507693A JP 2008536920 A JP2008536920 A JP 2008536920A
Authority
JP
Japan
Prior art keywords
antibody
protein
biological fluid
autoantibodies
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008507693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536920A5 (https=
Inventor
エー マッキンタイア、ジョン
Original Assignee
レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー filed Critical レドックス−リアクティブ リエイジェンツ リミテッド ライアビリティー カンパニー
Publication of JP2008536920A publication Critical patent/JP2008536920A/ja
Publication of JP2008536920A5 publication Critical patent/JP2008536920A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008507693A 2005-04-19 2006-04-06 酸化還元反応によるタンパク質の結合特異性の改変方法 Pending JP2008536920A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/108,826 US9557325B2 (en) 2003-06-09 2005-04-19 Method of altering the binding specificity of proteins by oxidation-reduction reactions
PCT/US2006/012802 WO2006113139A2 (en) 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions

Publications (2)

Publication Number Publication Date
JP2008536920A true JP2008536920A (ja) 2008-09-11
JP2008536920A5 JP2008536920A5 (https=) 2011-03-31

Family

ID=37115646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507693A Pending JP2008536920A (ja) 2005-04-19 2006-04-06 酸化還元反応によるタンパク質の結合特異性の改変方法

Country Status (9)

Country Link
US (1) US9557325B2 (https=)
EP (1) EP1871171A4 (https=)
JP (1) JP2008536920A (https=)
CN (1) CN101262774A (https=)
AU (1) AU2006236928B2 (https=)
BR (1) BRPI0608373A2 (https=)
CA (1) CA2602635C (https=)
MX (1) MX2007013171A (https=)
WO (1) WO2006113139A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
KR20220139237A (ko) * 2021-04-07 2022-10-14 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
AU2004248155B2 (en) * 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US8372387B2 (en) * 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US7989596B2 (en) * 2007-09-19 2011-08-02 Redox-Reactive Reagents Llc Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
EP2326952B1 (en) * 2008-09-04 2015-07-29 Redox-Reactive Reagents, Llc Method for diagnosing, monitoring, and/or staging alzheimer's disease
US20120107841A1 (en) * 2010-07-19 2012-05-03 Mcintyre John A Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease
CN102818896B (zh) * 2011-06-09 2014-12-17 北京华大蛋白质研发中心有限公司 一种基于特异抗体的硝基化修饰位点的检测方法及特异识别scot硝基化位点的抗体
EP2836845B1 (en) 2012-04-13 2018-05-09 DiabetOmics, Inc. Maternal biomarkers for gestational diabetes
WO2016081413A1 (en) * 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
ES2748117T3 (es) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnóstico de una nueva enfermedad autoinmune
CN113490539A (zh) * 2019-05-29 2021-10-08 松下知识产权经营株式会社 检测方法和检测装置
CN118526489B (zh) * 2024-05-24 2025-04-01 南通大学 一种脱镁叶绿酸乙酯的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111608A2 (en) * 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703001A (en) 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
US5061790A (en) 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
AU703814B2 (en) 1995-12-04 1999-04-01 Wyeth Antioxidant
US5939394A (en) 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111608A2 (en) * 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
KR20220139237A (ko) * 2021-04-07 2022-10-14 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
CA2602635A1 (en) 2006-10-26
MX2007013171A (es) 2008-01-18
CN101262774A (zh) 2008-09-10
AU2006236928A1 (en) 2006-10-26
AU2006236928B2 (en) 2011-06-23
US9557325B2 (en) 2017-01-31
EP1871171A4 (en) 2015-08-19
BRPI0608373A2 (pt) 2010-11-16
WO2006113139A3 (en) 2007-08-23
EP1871171A2 (en) 2008-01-02
CA2602635C (en) 2014-12-23
US20050260681A1 (en) 2005-11-24
WO2006113139A2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
JP4662557B2 (ja) 酸化還元反応による血漿タンパク質の結合特異性の改変方法
JP2008536920A (ja) 酸化還元反応によるタンパク質の結合特異性の改変方法
McIntyre The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation–reduction reactions
McIntyre et al. Autoantibodies unmasked by redox reactions
Wahrmann et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation
Fairchild et al. Specific immunoregulation abnormality in insulin-dependent diabetes mellitus
EP0877939B1 (en) Methods for the detection of alzheimer's disease
US7989596B2 (en) Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
JP4377207B2 (ja) 血液凝固時間測定方法および血液凝固時間測定用試薬
McIntyre et al. Autoantibody potential of cancer therapeutic monoclonal antibodies
MXPA05013402A (en) Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
Bloemen et al. Inverted erythrocyte membranes demonstrate β2GPI-antiphospholipid antibody interactions and membrane crosslinking
EP1142995B1 (en) Antiuracil monoclonal antibody
BRIMIJOIN et al. Paroxysmal nocturnal hemoglobinuria: erythrocyte acetylcholinesterase deficit analyzed by immunoassay and fluorescence-activated sorting
JPH08503770A (ja) 抗ｈｐａ抗体の検出

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110112

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308